EP Patent

EP3553059B1 — 8-bromo-1-methyl-6-(2-pyridinyl)-4h-imidazo[1,2-a][1,4]benzodiazepine-4-propanoic acid methyl ester (remimazolam, cns 7056) hydrobromide (1:1) salt for injection for sedation and anesthesia

Assigned to Chengdu Brilliant Pharmaceutical Co Ltd · Expires 2021-10-13 · 5y expired

What this patent protects

Patent listed against Tegretol.

Drugs covered by this patent

Patent Metadata

Patent number
EP3553059B1
Jurisdiction
EP
Classification
—
Expires
2021-10-13
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Brilliant Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.